The agreement now includes distribution of Roche's Kapa Biosystems portfolio in all geographies except the US, Brazil, and Japan.
Under the terms of the deal, Color Genomics will integrate Kapa Biosystems' library construction reagents into its NGS workflow.
The certification enables the reagent maker to create optimizing products for use beyond the research market.
Kapa offers "essential components" to Roche's overall NGS solution and enables Roche to improve the workflow of its NGS platforms.
Roche said the acquisition will strengthen its next-generation sequencing product offerings.
Kapa will supply DNA library prep reagents for 10X's GemCode platform to enable a more streamlined workflow and higher quality sequencing data.
Kapa will manufacture versions of its RNA-seq kits for distribution with Roche's RNA target enrichment system.
The firm will transition from its current partnership with Anachem to a direct sales and support channel in the UK as it expands its European operations.
NEW YORK (GenomeWeb) — Kapa Biosystems said today that it has signed a three-year exclusive distribution agreement with Nippon Genetics.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.